SM2256

SM2256: sourced facts only. name: "SM2256 exhibited sub-nanomolar binding affinity to recombinant human and cynomolgus monkey CD40 and 4-1BB, activating 4-1BB-NFκB-luc and CD40-NFκB-luc reporter cell lines at picomolar concentrations in a strictly target-dependent manner." [DOI:10.1158/1538-7445.am2024-5316]; target: "SM2256 exhibited sub-nanomolar binding affinity to recombinant human and cynomolgus monkey CD40 and 4-1BB, activating 4-1BB-NFκB-luc and CD40-NFκB-luc reporter cell lines at picomolar concentrations in a strictly target-dependent manner." [DOI:10.1158/1538-7445.am2024-5316]; target: "SM2256 exhibited sub-nanomolar binding affinity to recombinant human and cynomolgus monkey CD40 and 4-1BB, activating 4-1BB-NFκB-luc and CD40-NFκB-luc reporter cell lines at picomolar concentrations in a strictly target-dependent manner." [DOI:10.1158/1538-7445.am2024-5316]; developer: "1Beijing StarMab BioMed Technology, Ltd., Beijing, China." [DOI:10.1158/1538-7445.am2024-5316]; modality: "This fusion resulted in a tetravalent bispecific antibody capable of conditionally activating CD40 and 4-1BB upon mutual receptor binding." [DOI:10.1158/1538-7445.am2024-5316]; stage: "In a syngeneic tumor transplantation model, SM2256 significantly restrained the growth of MC38 tumors in B-h41BB/B-hCD40 double humanized mice." [DOI:10.1158/1538-7445.am2024-5316]